Goldynglow LLC – Trademark Portfolio

Entity Type: 16

Goldynglow LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 25 (Clothing) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include GOLDYNGLOW and GLOW DIGGER. The owner is based in Malibu, CA.

20734 Big Rock Drive

Malibu, CA 90265

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Goldynglow LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

25
Clothing (1 filing)

Clothing, footwear, headgear

41
Education & Entertainment (1 filing)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does Goldynglow LLC have?

Goldynglow LLC has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 cancelled.

What trademark classes does Goldynglow LLC file in?

Goldynglow LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 25 (Clothing), Class 41 (Education & Entertainment). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Goldynglow LLC's most well-known trademarks?

Goldynglow LLC's registered trademark portfolio includes well-known marks such as GOLDYNGLOW and GLOW DIGGER. These are among 2 currently registered trademarks in the portfolio.

What is Goldynglow LLC's trademark registration success rate?

Goldynglow LLC has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.